According to published reports, officals at the FDA will continue to allow access to ProAmatine, also known as midodrine, "while the necessary data is collected and the legal issues get sorted out."  Chelsea Therapuetics'(NASDAQ:CHTP) drug, Northera is set to compete against midodrine, however the FDA still yet to make a final ruling.

Last week, Pfizer agreed to acquire a privately held company called FoldRx Pharmaceuticals, whose leading drug candidate is a therapy for a genetic neurodegenerative disease for which the only current therapy is a liver transplant.

Large drug makers will likely continue to make acquisitions and sign pricey partnership deals do so after struggling to develop new "hit drugs" of their own.

Below is a list of the companies that made news in the healthcare sector on Thursday, September 02, 2010.

Athersys Inc.(NASDAQ:ATHX) has been on the rise the past few trading days, so subscribers need to be in the know. ATHX is one of the few biotechnology companies developing stem cell treatments that was not effected by a federal judge’s recent injunction against federal funding of human embryonic stem cell research, which the Obama administration is appealing.

Shares of Kraig Biocraft Laboratories, Inc. (OTCBB:KBLB) are on our watch list as we believe several potentially interesting developments may be close at hand.

Below is a list of the companies that made news in the healthcare sector on Wednesday, September 01, 2010.